AstraZeneca has entered into a definitive merger agreement to acquire Pearl Therapeutics for $560 million upfront and as much as $450 million if certain development and regulatory milestones are achieved for any triple combination therapies developed using Pearl’s technology platform. In addition, sales-related milestone payments could total $140 million. The acquisition adds Pearl’s pipeline of inhaled bronchodilator products for the treatment of COPD. The transaction is expected to...